Increase in prevalence and incidence of sexually transmitted diseases (STDS) globally is anticipated to be a key driver of the market. STD is predominant in lower and middle income countries and hence governments have been taken up various awareness programs and activities related to prevention and spread of STDs.
The Global Sexually Transmitted Diseases (STD) Diagnostics market is highly competitive with a strong presence of key players. Companies operating in this market have come up with advanced diagnostic products for early detection of sexually transmitted infections.
However, despite numerous initiatives undertaken by government bodies and private organizations, the awareness or diagnosis rate of sexually transmitted disease is limited at the ground level. This is likely to be a restraining factor in the STD diagnostics market during the forecast period.
Sexually transmitted diseases (STDs) originate from sexually transmitted infections (STIs). They spread mostly by sexual contact. STIs are impacted by bacteria, viruses or parasites. A sexually transmitted infection may pass from person to another through blood, semen, or vaginal and other bodily fluids.
Majorly, four types of diagnostic testing are used in sexually transmitted disease. Molecular test, serological test, point of care testing, and others that include immunological testing are used to detect Chlamydia, Gonorrhea, Syphilis, HIV, and other STD diseases. Point of care testing is the predominant test type for detection and diagnosis of STDs.
| Attribute | Detail |
|---|---|
| Driver |
|
Sexually transmitted diseases (STDs) pose a significant global health challenge. These diseases, including human immunodeficiency virus (HIV) infection, are among the most intricate conditions in modern medicine.
STDs exhibit a higher incidence and prevalence, particularly in developing nations, an alarming rate of antimicrobial resistance, a greater likelihood of severe complications, and a strong correlation with HIV infection.
According to the World Health Organization (WHO), in 2020, there were an estimated 374 million new infections of four common STIs: chlamydia (129 million), gonorrhea (82 million), syphilis (7.1 million), and trichomoniasis (156 million).
Genital herpes affected over 490 million individuals in 2016, while approximately 300 million women were estimated to have an HPV infection, which is the primary cause of cervical and anal cancer.
The most up-to-date and comprehensive data on nationally notifiable STIs for federally funded control programs can be found in the 2022 edition of Sexually Transmitted Infections Surveillance. This report serves as a vital resource for understanding the current landscape of STIs.
It is crucial to recognize that STIs must be prioritized as a public health concern, as emphasized in the Centers for Disease Control and Prevention's (CDC) annual report. In 2022 alone, the United States reported over 2.5 million cases of syphilis, gonorrhea, and chlamydia.
The sexually transmitted diseases (STD) diagnostics market segmentation based on type of diagnostic test includes molecular test, serologic test, point of care test, and others (immunological test etc.).
Point-of-care (POC) diagnostic tests are the market leader in sexually transmitted diseases (STD) diagnosis. POC tests offer several advantages that include rapid results, ease of use, and the ability to perform outside of traditional laboratory settings, making them highly valuable in the field.
Major players such as BD, Qiagen Diagnostics and Roche Diagnostics in the STD diagnostics market have focused on developing POC tests. These tests can be used in a variety of settings, including clinics, hospitals, and even at home. This accessibility makes it easier for more people to get tested, especially in areas with limited access to medical facilities.
POC tests are designed to be user-friendly, requiring minimal training to administer and interpret. This is beneficial in low-resource settings where specialist medical staff may not be available.
As per disease type, the rate of new HIV/AIDS diagnoses has increased rapidly and HIV/AIDS has become a major public health problem globally. In most countries, morbidity and mortality from HIV/AIDS are higher in men than in women and in young people than in older people.
In the past, HIV/AIDS prevention among the younger population was always a priority. However, the rate of HIV/AIDS infection in older people (>60 years old) increases faster than in younger groups and receives less attention. Several organizations and government agencies have developed public awareness campaigns about HIV diagnosis, treatment, and care.
A campaign which is sponsored by CDC called ‘Doing It’ creates awareness about the importance of HIV testing for all age groups. The campaign focuses on high-risk groups in the U.S. Another campaign named ‘One Test.
Two Lives’ emphasizes health care providers to test pregnant women for HIV to reduce the number of infants born with HIV. These campaigns and initiatives are expected to bolster the sexually transmitted diseases (STD) diagnostics market growth.
According to the sexually transmitted diseases (STD) diagnostics market analysis, the diagnostic laboratories segment is likely to dominate based on end-user. Diagnostic laboratories have access to the newest and most advanced diagnostic technologies.
These technologies help them to perform an extensive range of tests with high accuracy, including molecular tests, immunoassays, and point-of-care tests, which is vital to manage public health and control the spread of STDs. This is crucial during outbreaks or in areas with high prevalence rates.
Private diagnostic laboratories and leading diagnostic service providers are working collaboratively with leading players. In November 2021, MedAccess and SD Biosensors announced a partnership to significantly increase access to innovative combined rapid tests for syphilis and HIV.
SD Biosensor's STANDARD Q HIV/syphilis combination test became the first World Health Organization (WHO) pre-qualified HIV/syphilis combination test available for less than US$ 1 to public sector purchasers in low- and middle-income countries.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
As per the latest sexually transmitted diseases (STD) diagnostics market forecast, North America dominates the landscape. The increase in incidence of sexually transmitted infections (STIs) is driving market dynamics in the region.
This increase is especially pronounced among adolescents 15 to 24 years old. Although they make up only a quarter of the population, adolescents account for about half of new STI cases in the United States each year.
The Centers for Disease Control and Prevention (CDC) released 2021 STD surveillance data, showing that sexually transmitted infections have reached a new record for the eighth consecutive year.
The data shows an approximately 74% increase in syphilis rates over five years, as well as 2,800 cases of congenital syphilis in 2021, of which 220 resulted in infant death. The data also shows that chlamydia rates have increased to pre-pandemic levels after cases went undetected during the first year of the COVID-19 pandemic.
According to the sexually transmitted diseases (STD) diagnostics market report, leading players are adopting strategies such as development of products and collaborative partnerships.
F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Hologic Inc., Creative Diagnostics, Abbott Laboratories, Quest Diagnostics, BD, QIAGEN, Cepheid, and bioMérieux Inc.are the prominent sexually transmitted diseases (STD) diagnostics market players.
Each of these players have been profiled in the sexually transmitted diseases (STD) diagnostics market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Market Value in 2023 | US$ 7.1 Bn |
| Forecast (Value) in 2034 | US$ 15.9 Bn |
| Growth Rate (CAGR) | 7.6% |
| Forecast Period | 2024-2034 |
| Historical Data Available for | 2020-2022 |
| Quantitative Units | US$ Mn for Value |
| Market Analysis | It provides segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 7.1 Bn in 2023
It is projected to reach more than US$ 15.9 Bn by the end of 2034
The CAGR is anticipated to be 7.6% from 2024 to 2034
Advancements in diagnostic technology and increase in government efforts to promote early detection and treatment
Based on type of diagnostic test, the point of care test segment accounted for major share in 2023
North America is expected to account for major share during the forecast period
F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Hologic Inc., Creative Diagnostics, Abbott Laboratories, Quest Diagnostics, BD, QIAGEN, Cepheid, and bioMérieux Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Sexually Transmitted Diseases (STD) Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Segment Definition
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecasts, 2020-2034
5. Key Insights
5.1. Key Product & Brand Analysis
5.2. Porter’s Five Forces Analysis
5.3. CDC’s 2022 Sexually Transmitted Disease (STI) Surveillance
5.4. Insights on Sexually Transmitted Infections in Low and Middle Income Countries
6. Global Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecasts, By Type of Diagnostic Test
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast By Type of Diagnostic Test, 2020-2034
6.3.1. Molecular Test
6.3.2. Serologic Test
6.3.3. Point of Care Test
6.3.4. Others (Immunological Test etc.)
6.4. Market Attractiveness By Type of Diagnostic Test
7. Global Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecasts, By Disease Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast By Disease Type, 2020-2034
7.3.1. Chlamydia
7.3.2. Gonorrhea
7.3.3. Syphilis
7.3.4. HIV/AIDS
7.3.5. Human Papillomavirus (HPV)
7.3.6. Genital Herpes
7.3.7. Others STDs
7.4. Market Attractiveness By Disease Type
8. Global Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecasts, By End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast By End-user, 2020-2034
8.3.1. Hospitals & Clinics
8.3.2. Diagnostic Laboratories
8.3.3. Others (Research Institutes, Homecare Settings etc.)
8.4. Market Attractiveness By End-user
9. Global Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecasts, By Region
9.1. Key Findings
9.2. Market Value Forecast By Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness By Country/Region
10. North America Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast By Type of Diagnostic Test, 2020-2034
10.2.1. Molecular Test
10.2.2. Serologic Test
10.2.3. Point of Care Test
10.2.4. Others (Immunological Test etc.)
10.3. Market Value Forecast By Disease Type, 2020-2034
10.3.1. Chlamydia
10.3.2. Gonorrhea
10.3.3. Syphilis
10.3.4. HIV/AIDS
10.3.5. Human Papillomavirus (HPV)
10.3.6. Genital Herpes
10.3.7. Others STDs
10.4. Market Value Forecast By End-user, 2020-2034
10.4.1. Hospitals & Clinics
10.4.2. Diagnostic Laboratories
10.4.3. Others (Research Institutes, Homecare Settings etc.)
10.5. Market Value Forecast By Country, 2020-2034
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Type of Diagnostic Test
10.6.2. By Disease Type
10.6.3. By End-user
10.6.4. By Country
11. Europe Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast By Type of Diagnostic Test, 2020-2034
11.2.1. Molecular Test
11.2.2. Serologic Test
11.2.3. Point of Care Test
11.2.4. Others (Immunological Test etc.)
11.3. Market Value Forecast By Disease Type, 2020-2034
11.3.1. Chlamydia
11.3.2. Gonorrhea
11.3.3. Syphilis
11.3.4. HIV/AIDS
11.3.5. Human Papillomavirus (HPV)
11.3.6. Genital Herpes
11.3.7. Others STDs
11.4. Market Value Forecast By End-user, 2020-2034
11.4.1. Hospitals & Clinics
11.4.2. Diagnostic Laboratories
11.4.3. Others (Research Institutes, Homecare Settings etc.)
11.5. Market Value Forecast By Country, 2020-2034
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Type of Diagnostic Test
11.6.2. By Disease Type
11.6.3. By End-user
11.6.4. By Country
12. Asia Pacific Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast By Type of Diagnostic Test, 2020-2034
12.2.1. Molecular Test
12.2.2. Serologic Test
12.2.3. Point of Care Test
12.2.4. Others (Immunological Test etc.)
12.3. Market Value Forecast By Disease Type, 2020-2034
12.3.1. Chlamydia
12.3.2. Gonorrhea
12.3.3. Syphilis
12.3.4. HIV/AIDS
12.3.5. Human Papillomavirus (HPV)
12.3.6. Genital Herpes
12.3.7. Others STDs
12.4. Market Value Forecast By End-user, 2020-2034
12.4.1. Hospitals & Clinics
12.4.2. Diagnostic Laboratories
12.4.3. Others (Research Institutes, Homecare Settings etc.)
12.5. Market Value Forecast By Country, 2020-2034
12.5.1. China
12.5.2. India
12.5.3. Japan
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Type of Diagnostic Test
12.6.2. By Disease Type
12.6.3. By End-user
12.6.4. By Country
13. Latin America Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast By Type of Diagnostic Test, 2020-2034
13.2.1. Molecular Test
13.2.2. Serologic Test
13.2.3. Point of Care Test
13.2.4. Others (Immunological Test etc.)
13.3. Market Value Forecast By Disease Type, 2020-2034
13.3.1. Chlamydia
13.3.2. Gonorrhea
13.3.3. Syphilis
13.3.4. HIV/AIDS
13.3.5. Human Papillomavirus (HPV)
13.3.6. Genital Herpes
13.3.7. Others STDs
13.4. Market Value Forecast By End-user, 2020-2034
13.4.1. Hospitals & Clinics
13.4.2. Diagnostic Laboratories
13.4.3. Others (Research Institutes, Homecare Settings etc.)
13.5. Market Value Forecast By Country, 2020-2034
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Type of Diagnostic Test
13.6.2. By Disease Type
13.6.3. By End-user
13.6.4. By Country
14. Middle East & Africa Sexually Transmitted Diseases (STD) Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast By Type of Diagnostic Test, 2020-2034
14.2.1. Molecular Test
14.2.2. Serologic Test
14.2.3. Point of Care Test
14.2.4. Others (Immunological Test etc.)
14.3. Market Value Forecast By Disease Type, 2020-2034
14.3.1. Chlamydia
14.3.2. Gonorrhea
14.3.3. Syphilis
14.3.4. HIV/AIDS
14.3.5. Human Papillomavirus (HPV)
14.3.6. Genital Herpes
14.3.7. Others STDs
14.4. Market Value Forecast By End-user, 2020-2034
14.4.1. Hospitals & Clinics
14.4.2. Diagnostic Laboratories
14.4.3. Others (Research Institutes, Homecare Settings etc.)
14.5. Market Value Forecast By Country, 2020-2034
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Type of Diagnostic Test
14.6.2. By Disease Type
14.6.3. By End-user
14.6.4. By Country
15. Competition Landscape
15.1. Market Player - Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis By Company (2023)
15.3. Company Profiles
15.3.1. F. Hoffmann-La Roche Ltd
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Thermo Fisher Scientific Inc.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Hologic Inc.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Creative Diagnostics
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Abbott Laboratories
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Quest Diagnostics
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. BD
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. QIAGEN
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Cepheid
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.10. bioMérieux
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
List of Tables
Table 01: Global STD Diagnostics Market Value (US$ Mn) Forecast, by Type of Diagnostic Test, 2020-2034
Table 02: Global STD Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 03: Global STD Diagnostics Market Value (US$ Mn) Forecast, by Disease Type, 2020-2034
Table 04: Global STD Diagnostics Market Value (US$ Mn) Forecast, by Region, 2020-2034
Table 05: North America STD Diagnostics Market Value (US$ Mn) Forecast, by Country, 2020-2034
Table 06: Asia Pacific STD Diagnostics Market Value (US$ Mn) Forecast, by Type of Diagnostic Test, 2020-2034
Table 07: Europe STD Diagnostics Market Value (US$ Mn) Forecast, by Type of Diagnostic Test, 2020-2034
Table 08: Latin America STD Diagnostics Market Value (US$ Mn) Forecast, by Type of Diagnostic Test, 2020-2034
Table 09: Middle East & Africa STD Diagnostics Market Value (US$ Mn) Forecast, by Type of Diagnostic Test, 2020-2034
Table 10: North America STD Diagnostics Market Value (US$ Mn) Forecast, by Type of Diagnostic Test, 2020-2034
Table 11: Asia Pacific STD Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 12: Europe STD Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 13: Latin America STD Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 14: Middle East & Africa STD Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 15: North America STD Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2020-2034
Table 16: Asia Pacific STD Diagnostics Market Value (US$ Mn) Forecast, by Disease Type, 2020-2034
Table 17: Europe STD Diagnostics Market Value (US$ Mn) Forecast, by Disease Type, 2020-2034
Table 18: Latin America STD Diagnostics Market Value (US$ Mn) Forecast, by Disease Type, 2020-2034
Table 19: Middle East & Africa STD Diagnostics Market Value (US$ Mn) Forecast, by Disease Type, 2020-2034
Table 20: North America STD Diagnostics Market Value (US$ Mn) Forecast, by Disease Type, 2020-2034
Table 21: Asia Pacific STD Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 22: Europe STD Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 23: Latin America STD Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
Table 24: Middle East & Africa STD Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2020-2034
List of Figures
Figure 01: Global STD Diagnostics Market Value (US$ Mn) Forecast, 2020-2034
Figure 02: Global STD Diagnostics Market Value Share, by Type of Diagnostic Test, 2023
Figure 03: Global STD Diagnostics Market Value Share, by Disease Type, 2023
Figure 04: Global STD Diagnostics Market Value Share, by End-user, 2023
Figure 05: Global STD Diagnostics Market Value (US$ Mn) Share Analysis, by Type of Diagnostic Test, 2023 and 2034
Figure 06: Global STD Diagnostics Market Share Analysis, by Type of Diagnostic Test, 2022
Figure 07: Global STD Diagnostics Market Share Analysis, by Type of Diagnostic Test, 2031
Figure 08: Global STD Diagnostics Market Attractiveness Analysis, by Type of Diagnostic Test, 2024-2034
Figure 09: Global STD Diagnostics Market Value (US$ Mn), by Molecular Test, 2017-2031
Figure 10: Global STD Diagnostics Market Value Share Analysis, by Molecular Test, 2023 and 2034
Figure 11: Global STD Diagnostics Market Value (US$ Mn), by Serologic Test, 2017-2031
Figure 12: Global STD Diagnostics Market Value Share Analysis, by Serologic Test, 2023 and 2034
Figure 13: Global STD Diagnostics Market Value (US$ Mn), by Point of Care Test, 2017-2031
Figure 14: Global STD Diagnostics Market Value Share Analysis, by Point of Care Test, 2023 and 2034
Figure 15: Global STD Diagnostics Market Value (US$ Mn), by Others, 2017-2031
Figure 16: Global STD Diagnostics Market Value Share Analysis, by Others, 2023 and 2034
Figure 17: Global STD Diagnostics Market Value (US$ Mn) Share Analysis, by Disease Type, 2023 and 2034
Figure 18: Global STD Diagnostics Market Share Analysis, by Disease Type, 2022
Figure 19: Global STD Diagnostics Market Share Analysis, by Disease Type, 2031
Figure 20: Global STD Diagnostics Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 21: Global STD Diagnostics Market Value (US$ Mn), by Clinical Disease Type, 2017-2031
Figure 22: Global STD Diagnostics Market Value Share Analysis, by Chlamydia, 2023 and 2034
Figure 23: Global STD Diagnostics Market Value (US$ Mn), by Gonorrhea, 2017-2031
Figure 24: Global STD Diagnostics Market Value Share Analysis, by Gonorrhea, 2023 and 2034
Figure 25: Global STD Diagnostics Market Value (US$ Mn), by Syphilis, 2017-2031
Figure 26: Global STD Diagnostics Market Value Share Analysis, by Syphilis, 2023 and 2034
Figure 27: Global STD Diagnostics Market Value (US$ Mn), by HIV/AIDS, 2017-2031
Figure 28: Global STD Diagnostics Market Value Share Analysis, by HIV/AIDS, 2023 and 2034
Figure 29: Global STD Diagnostics Market Value (US$ Mn), by Human Papillomavirus (HPV), 2017-2031
Figure 30: Global STD Diagnostics Market Value Share Analysis, by Human Papillomavirus (HPV), 2023 and 2034
Figure 31: Global STD Diagnostics Market Value (US$ Mn), by Genital Herpes, 2017-2031
Figure 32: Global STD Diagnostics Market Value Share Analysis, by Genital Herpes, 2023 and 2034
Figure 33: Global STD Diagnostics Market Value (US$ Mn), by Others, 2017-2031
Figure 34: Global STD Diagnostics Market Value Share Analysis, by Others, 2023 and 2034
Figure 35: Global STD Diagnostics Market Value (US$ Mn) Share Analysis, by End-user, 2023 and 2034
Figure 36: Global STD Diagnostics Market Share Analysis, by End-user, 2022
Figure 37: Global STD Diagnostics Market Share Analysis, by End-user, 2031
Figure 38: Global STD Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 39: Global STD Diagnostics Market Value (US$ Mn), by Hospitals & Clinics, 2017-2031
Figure 40: Global STD Diagnostics Market Value Share Analysis, by Hospitals & Clinics, 2023 and 2034
Figure 41: Global STD Diagnostics Market Value (US$ Mn), by Diagnostic Laboratories, 2017-2031
Figure 42: Global STD Diagnostics Market Value Share Analysis, by Diagnostic Laboratories, 2023 and 2034
Figure 43: Global STD Diagnostics Market Value (US$ Mn), by Others, 2017-2031
Figure 44: Global STD Diagnostics Market Value Share Analysis, by Others, 2023 and 2034
Figure 45: Global STD Diagnostics Market Value Share Analysis, by Region, 2023 and 2034
Figure 46: Global STD Diagnostics Market Share Analysis, by Region, 2022
Figure 47: Global STD Diagnostics Market Share Analysis, by Region, 2031
Figure 48: Global STD Diagnostics Market Attractiveness Analysis, by Region, 2024-2034
Figure 49: North America STD Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 50: North America STD Diagnostics Market Attractiveness Analysis, by Country, 2024-2034
Figure 51: North America STD Diagnostics Market Value (US$ Mn) Share Analysis, by Type of Diagnostic Test, 2023 and 2034
Figure 52: North America STD Diagnostics Market Attractiveness Analysis, by Type of Diagnostic Test, 2024-2034
Figure 53: North America STD Diagnostics Market Value (US$ Mn) Share Analysis, by Disease Type, 2023 and 2034
Figure 54: North America STD Diagnostics Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 55: North America STD Diagnostics Market Value (US$ Mn) Share Analysis, by End-user, 2023 and 2034
Figure 56: North America STD Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 57: Europe STD Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 58: Europe STD Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 59: Europe STD Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 60: North America STD Diagnostics Market Value (US$ Mn) Share Analysis, by Type of Diagnostic Test, 2023 and 2034
Figure 61: North America STD Diagnostics Market Attractiveness Analysis, by Type of Diagnostic Test, 2024-2034
Figure 62: Europe STD Diagnostics Market Value (US$ Mn) Share Analysis, by Disease Type, 2023 and 2034
Figure 63: Europe STD Diagnostics Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 64: Europe STD Diagnostics Market Value (US$ Mn) Share Analysis, by End-user, 2023 and 2034
Figure 65: Europe STD Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 66: Asia Pacific STD Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection,2020-2034
Figure 67: Asia Pacific STD Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 68: Asia Pacific STD Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 69: Asia Pacific STD Diagnostics Market Value (US$ Mn) Share Analysis, by Type of Diagnostic Test, 2023 and 2034
Figure 70: Asia Pacific STD Diagnostics Market Attractiveness Analysis, by Type of Diagnostic Test, 2024-2034
Figure 71: Asia Pacific STD Diagnostics Market Value (US$ Mn) Share Analysis, by Disease Type, 2023 and 2034
Figure 72: Asia Pacific STD Diagnostics Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 73: Asia Pacific STD Diagnostics Market Value (US$ Mn) Share Analysis, by End-user, 2023 and 2034
Figure 74: Asia Pacific STD Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 75: Latin America STD Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 76: Latin America STD Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 77: Latin America STD Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 78: Latin America STD Diagnostics Market Value (US$ Mn) Share Analysis, by Type of Diagnostic Test, 2023 and 2034
Figure 79: Latin America STD Diagnostics Market Attractiveness Analysis, by Type of Diagnostic Test, 2024-2034
Figure 80: Latin America STD Diagnostics Market Value (US$ Mn) Share Analysis, by Disease Type, 2023 and 2034
Figure 81: Latin America STD Diagnostics Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 82: Latin America STD Diagnostics Market Value (US$ Mn) Share Analysis, by End-user, 2023 and 2034
Figure 83: Latin America STD Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
Figure 84: Middle East & Africa STD Diagnostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2020-2034
Figure 85: Middle East & Africa STD Diagnostics Market Value Share Analysis, by Country/Sub-region, 2023 and 2034
Figure 86: Middle East & Africa STD Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2024-2034
Figure 87: Middle East & Africa STD Diagnostics Market Value (US$ Mn) Share Analysis, by Type of Diagnostic Test, 2023 and 2034
Figure 88: Middle East & Africa STD Diagnostics Market Attractiveness Analysis, by Type of Diagnostic Test, 2024-2034
Figure 89: Middle East & Africa STD Diagnostics Market Value (US$ Mn) Share Analysis, by Disease Type, 2023 and 2034
Figure 90: Middle East & Africa STD Diagnostics Market Attractiveness Analysis, by Disease Type, 2024-2034
Figure 91: Middle East & Africa STD Diagnostics Market Value (US$ Mn) Share Analysis, by End-user, 2023 and 2034
Figure 92: Middle East & Africa STD Diagnostics Market Attractiveness Analysis, by End-user, 2024-2034
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Sexually Transmitted Diseases (STD) Diagnostics Market
